share_log

HC Wainwright & Co. Reiterates Buy on Lexeo Therapeutics, Maintains $23 Price Target

Benzinga ·  Mar 26 10:45

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 357

Recommended

Write a comment